Lineage Cell Therapeutics
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lineage Cell Therapeutics
Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.
Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
- Drug Delivery
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Asterias Biotherapeutics, Inc.
- BioTime Acquisition Corp.
- BioTime, Inc.
- Cell Cure Neurosciences Ltd.
- Embryome Sciences
- ES Cell International Pte Ltd
- LifeMap Sciences, Inc.
- OncoCyte Corporation
- ReCyte Therapeutics